A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.

Jain N, Senapati J, Thakral B, Ferrajoli A, Thompson P, Burger J, Basu S, Kadia T, Daver N, Borthakur G, Konopleva M, Pemmaraju N, Parry E, Wu CJ, Khoury J, Bueso-Ramos C, Garg N, Wang X, Lopez W, Ayala A, O'Brien S, Kantarjian H, Keating M, Allison J, Sharma P, Wierda W

Open source

DOI: 10.1182/bloodadvances.2022008790
Published: 2023 May 23
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2022008790,
  title = {A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.},
  author = {Jain N and Senapati J and Thakral B and Ferrajoli A and Thompson P and Burger J and Basu S and Kadia T and Daver N and Borthakur G and Konopleva M and Pemmaraju N and Parry E and Wu CJ and Khoury J and Bueso-Ramos C and Garg N and Wang X and Lopez W and Ayala A and O'Brien S and Kantarjian H and Keating M and Allison J and Sharma P and Wierda W},
  year = {2023},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2022008790},
  url = {https://doi.org/10.1182/bloodadvances.2022008790}
}

RIS

TY  - JOUR
TI  - A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.
AU  - Jain N
AU  - Senapati J
AU  - Thakral B
AU  - Ferrajoli A
AU  - Thompson P
AU  - Burger J
AU  - Basu S
AU  - Kadia T
AU  - Daver N
AU  - Borthakur G
AU  - Konopleva M
AU  - Pemmaraju N
AU  - Parry E
AU  - Wu CJ
AU  - Khoury J
AU  - Bueso-Ramos C
AU  - Garg N
AU  - Wang X
AU  - Lopez W
AU  - Ayala A
AU  - O'Brien S
AU  - Kantarjian H
AU  - Keating M
AU  - Allison J
AU  - Sharma P
AU  - Wierda W
PY  - 2023
JO  - Blood advances
DO  - 10.1182/bloodadvances.2022008790
UR  - https://doi.org/10.1182/bloodadvances.2022008790
ER  -

APA

N, J., J, S., B, T., A, F., P, T., J, B., S, B., T, K., N, D., G, B., M, K., N, P., E, P., CJ, W., J, K., C, B., N, G., X, W., W, L., A, A., S, O., H, K., M, K., J, A., P, S., & W, W. (2023). A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL.. Blood advances. https://doi.org/10.1182/bloodadvances.2022008790

Source records

pubmed · retrieved 2026-09-27T00:22:51.366Z